Patrys makes bold clinical-stage move with acquisition of WA private company Reliis, adding high-value delirium asset to ignite next phase of growth
Patrys Limited (ASX: PAB) has taken a major strategic leap forward this week, securing Reliis, a private Western Australian clinical-stage pharmaceutical company, and its proprietary injectable antipsychotic RLS-2201, a move that positions the company for a step-change in value and opens the door to a US$2 billion global delirium market with no approved therapies.
The transaction is one of Patrys’ most transformative to date, adding a near-term, lower-risk Central Nervous System (CNS) asset that complements its biologics platform while materially strengthening its clinical pipeline and broadening its shots on goal.
A smart expansion into a massive unmet market
Delirium is one of the most costly and dangerous acute-care conditions, affecting more than 500 million people annually and costing the US health system an estimated US$80 billion. Up to 80% of ventilated ICU patients experience delirium, yet clinicians have no approved rapid-acting treatments at their disposal.
Reliis’ RLS-2201, a proprietary IV formulation of the widely used antipsychotic quetiapine, is engineered specifically for the critical-care environments where oral medicines are slow, unpredictable and difficult to titrate. Strong clinical demand for an injectable option has been consistent for years, giving the asset a clear commercial and clinical runway.
Patrys: a deliberate shift to a stronger, more balanced pipeline
Patrys director Dr Anton Uvarov said the acquisition is a strategic step designed to reshape the company’s risk profile and accelerate value creation.
“The Acquisition of Reliis represents a deliberate strategic step to broaden Patrys’ pipeline and reduce binary development risk. RLS-2201 offers a materially shorter pathway to human data and clear near-term clinical and regulatory catalysts, complementing Patrys’ existing biologics program rather than diverting focus from it.
This addition creates a more balanced portfolio, combining high-value, longer-term biologics opportunities with a near-term, lower-risk pharmaceutical asset, thereby strengthening the Company’s overall risk–reward profile and accelerating its path to value creation.”
Investors have increasingly favoured companies with diversified pipelines and multiple clinical catalysts, making Patrys’ strategic pivot well aligned with prevailing sector trends.
A de-risked development plan with rapid value catalysts
Reliis’ RLS-2201 leverages existing safety and pharmacology data for quetiapine, enabling Reliis – now Patrys - to pursue the FDA 505(b)(2) and EMA abridged pathways commonly used for hospital-focused reformulations.
These pathways have been the backbone of several high-value transactions in recent years. The most notable is the US$1.4 billion acquisition of Ofirmev, an IV formulation of acetaminophen that validated the commercial potential of hospital-administered reformulations. Teva’s acquisition of rights to an injectable risperidone reformulation added a further US$117 million in potential milestones and royalties, and GSK’s partnership with Spero Therapeutics for a novel oral formulation of an approved IV antibiotic carried up to US$591 million in potential value.
Across the sector, 505(b)(2) products have consistently commanded strong deal premiums due to their lower development risk, faster paths to revenue, and clear hospital-market demand, a landscape into which RLS-2201 is ideally positioned.
Patrys will now move quickly into manufacturing, regulatory engagement and a Phase 0 PK study, followed by a Phase I ICU safety trial, a development arc designed to unlock meaningful clinical data sooner than traditional biologics programs typically allow.
Reliis: a partnership that accelerates clinical impact
Reliis Managing Director Dino Cercarelli said Patrys is the right partner to progress RLS-2201 toward patients and commercial value.
“This transaction creates a clear pathway to unlock the full value of RLS-2201 and deliver meaningful returns to shareholders. Patrys brings the scale, capability and capital markets presence needed to accelerate development and drive the program toward first-in-human evaluation.
Clinicians have been telling us for years that an intravenous quetiapine option is urgently needed, and this partnership now positions the asset to reach those patients sooner.
By combining our reformulation expertise with Patrys’ established platform, we believe we have created a significantly stronger vehicle to translate clinical demand into long-term commercial and shareholder value.”
Board strengthened with high-calibre additions
Under the transaction, Reliis co-founders Leanne Kite and Dino Cercarelli will join the Patrys Board, bringing ASX-200 governance experience, capital markets strategy, clinical operations expertise and deep sector networks, all assets that enhance Patrys’ strategic capability at a pivotal growth stage.
Investor outlook: momentum building
With a large, clearly defined market, strong clinician pull, accelerated regulatory pathways and near-term clinical milestones ahead, the acquisition positions Patrys for a strengthened growth trajectory and multiple opportunities for value creation.
If RLS-2201 progresses as expected, Patrys will enter 2026 with:
- a near-term CNS asset targeting a blockbuster-scale market;
- a strengthened and diversified clinical pipeline;
- more frequent clinical and commercial catalysts; and
- a significantly enhanced risk-reward profile.
For investors looking for a clinical-stage ASX biotech with both short-term catalysts and long-term innovation potential, Patrys’ acquisition of Reliis positions the company as one of the sector’s most compelling emerging growth stories.
By Leanne Kite
